Calithera is a leading brand in the field of tumor metabolism and tumor immunology. They specialize in the development of innovative small molecule drugs that effectively slow down tumor growth. By carefully controlling key metabolic pathways within both tumor cells and immune cells, Calithera delivers groundbreaking treatments that redefine the way we approach precision oncology.

Until recently, Calithera Biosciences was focused on developing targeted therapies to cater to specific patient populations based on biomarkers. However, in light of strategic considerations, their Board of Directors approved the dissolution and liquidation of the company. Consequently, they are in the process of discontinuing clinical programs and winding up operations.

Stockholders were scheduled to convene for a special meeting to approve the Plan of Dissolution, but unfortunately, a quorum was not achieved, leading to its cancellation. Despite the company's ongoing changes, Calithera remains committed to delivering impactful solutions in the realm of tumor metabolism and tumor immunology. They strive to unlock new possibilities in cancer treatment and leave a lasting impact on the field